Circulating microRNAs as Prognostic and Predictive Biomarkers in Patients with Colorectal Cancer

Schou, Jesper Sølver; Johansen, Julia S.; Nielsen, Dorte; Rossi, Simona

doi:10.3390/ncrna2020005

Cited by 10 publications

(14 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These alterations are specific for each malignancy, including various BC subtypes [ 4 , 5 , 7 , 9 , 15 – 18 ]. Thereby, circulating miRNAs are potential biomarkers in the case of numerous diseases [ 19 ], such as BC [ 15 , 20 – 22 ]. The studies undertaken to prove the causative effect of miRNA first perform a general profiling of clinical samples, then are followed by controlled experiments [ 22 – 26 ].…”

Section: Introductionmentioning

confidence: 99%

Aberrant miRNAs expressed in HER-2 negative breast cancers patient

Braicu

Ráduly

Morar-Bolba

et al. 2018

J Exp Clin Cancer Res

View full text Add to dashboard Cite

BackgroundBreast cancer is a highly heterogeneous pathology, exhibiting a number of subtypes commonly associated with a poor outcome. Due to their high stability, microRNAs are often regarded as non-invasive cancer biomarkers, having an expression pattern specific for their ‘cell of origin’.MethodTriple negative breast cancer (TNBC: ER-, PR-, Her-2-) and double positive breast cancer (DPBC: ER+, PR+, Her-2) miRNA expression patterns were obtained by analysis of the TCGA (The Cancer Genome Atlas) data, followed by PCR-array analysis on plasma samples from 20 TNBC patients, 14 DPBC patients and 11 controls.ResultsThree downregulated and nine upregulated miRNAs were obtained from the TNBC analysis. Five overexpressed miRNAs were identified in the DPBC group. Four of the dysregulated miRNAs (miR-10a, miR-125b, miR-210 and miR-489) were common for both groups. The cluster miR-17-92 (miR-17, miR-20a, miR-20b, and miR-93), along with miR-130, miR-22 and miR-29a/c, were found to differentiate between TNBC and DPBC. A panel of five transcripts (miR-10a, miR-125, miR-193b, miR-200b and miR-489) was validated in a new set of plasma samples. The overlapping of TCGA and plasma profiling data revealed miR-200b, miR-200c, miR-210 and miR-29c as common signature. MiR-200b was validated on additional normal and tumor tissue samples. The expression level of this transcript from the TCGA data was correlated with lung and bone metastatic genes.ConclusionThe miR-200b presents a great potential for the future advancements in the diagnostic/prognostic and therapeutic approach of TNBC, along with other coding or non-coding transcripts. However, this needs to be further integrated in a regulatory network that acts in conjunction with other markers that affect the patients’ prognosis or response to therapy.Electronic supplementary materialThe online version of this article (10.1186/s13046-018-0920-2) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

Aberrant miRNAs expressed in HER-2 negative breast cancers patient

Braicu

Ráduly

Morar-Bolba

et al. 2018

J Exp Clin Cancer Res

View full text Add to dashboard Cite

show abstract

“…It reported that miRNAs can be secreted by different cells and have been discovered in the bloodstream and bodily fluids [ 54–58 ]. Circulating miRNAs have the potential to be utilized as novel biomarkers for the early diagnosis, treatment and prognosis of several diseases, such as cancer [ 59 ], cardiovascular diseases [ 60 , 61 ], obesity [ 62 ], and diabetes mellitus [ 63 ]. Recent studies demonstrated that serum miRNA levels were markedly up-regulated in patients with osteoporotic fractures and could impact osteogenic differentiation [ 56 ].…”

Section: Circulating Mirnas In Osteoporosis and Bone Fracturementioning

confidence: 99%

The emerging role of microRNAs in bone remodeling and its therapeutic implications for osteoporosis

Feng

Zheng

2018

Bioscience Reports

View full text Add to dashboard Cite

Osteoporosis, a common and multifactorial disease, is influenced by genetic factors and environments. However, the pathogenesis of osteoporosis has not been fully elucidated yet. Recently, emerging evidence suggests that epigenetic modifications may be the underlying mechanisms that link genetic and environmental factors with increased risks of osteoporosis and bone fracture. MicroRNA (miRNA), a major category of small noncoding RNA with 20–22 bases in length, is recognized as one important epigenetic modification. It can mediate post-transcriptional regulation of target genes with cell differentiation and apoptosis. In this review, we aimed to profile the role of miRNA in bone remodeling and its therapeutic implications for osteoporosis. A deeper insight into the role of miRNA in bone remodeling and osteoporosis can provide unique opportunities to develop a novel diagnostic and therapeutic approach of osteoporosis.

show abstract

“…Certain ncRNAs were found to regulate p53-dependent gene control (21,22). Th ese include microRNAs such as miR-660 and miR-486, which are p53-dependent, and long non-coding RNAs (lncRNAs) such as TUG1 (taurine upregulated gene 1), the p53/TUG1/polycomb repressive complex-2 (PRC2)/homeodomain-containing protein (HOXB7) interaction as targets for the diagnosis and treatment of non-small cell lung carcinoma (NSCLC), miR-34, LincRNA-p21, p53 induced non-coding transcript (Pint) and p21-associated ncRNA DNA damage-activated (PANDA) (24-30) ( Table 1).…”

Section: P53-regulated Mirnasmentioning

confidence: 99%

New insights into the role of non-coding RNAs as transcriptional targets of p53

Cătană¹,

Gulei²,

Berindan‐Neagoe³

2017

Mol.Life

View full text Add to dashboard Cite

undergoes programmed cell death (6). Th e main role of p53 as a carcinogenic inhibitor consists in the regulation at the transcriptional level of the target genes that control various cellular processes including programmed cell death, DNA repair mechanisms, autophagy, metabolism, cell cycle control and thus genetic integrity (7-10). Th e elements targeted by p53, a cancer suppressor interacting with numerous target genes, were presented through meta-analysis statistics, which showed that the target genes characterized by high confi dence are involved in numerous feedback loops at cellular level such as cell cycle arrest, metabolism, and mRNA translation. At the same time, a series of mechanisms were associated with the modulatory aspects of gene control in response to p53 (11-13). To our knowledge, research studies revealed that p53 can act as a catalyst of transcription. Moreover, gene down-regulation by p53 is indirect and Abstract P53 classifies as one of the main tumor suppressor gene and the identification of its direct transcriptional targets such as certain non-coding RNAs (ncRNAs) is important for understanding the development and progression of cancer. Multiple ncRNAs are targeting p53 and are involved in many cellular processes such as cell cycle arrest, metabolism, apoptosis, autophagy and feedback mechanisms. Also, various ncRNAs were found to modulate p53-dependent gene regulation. These include microRNAs such as miR-660, miR-486, miR-34 and lncRNAs such as nuclear enriched abundant transcript 1 (NEAT1), which contribute to the tumor-suppressor function of the p53 protein. Long intergenic non-coding RNA, LincRNA-p21, has been proclaimed to promote apoptosis while other p53-regulated lncRNAs including PANDA and Pint antagonize p53 activity by limiting the activation of proapoptotic genes. Taking into account the activity of the proapoptotic transcription factor p53, new conclusions point to a new concept of cellular quality control since ncRNAs-based deregulation in cancer functions in the absence of p53 coding sequence mutations.

show abstract

Circulating microRNAs as Prognostic and Predictive Biomarkers in Patients with Colorectal Cancer

Cited by 10 publications

References 45 publications

Aberrant miRNAs expressed in HER-2 negative breast cancers patient

Aberrant miRNAs expressed in HER-2 negative breast cancers patient

The emerging role of microRNAs in bone remodeling and its therapeutic implications for osteoporosis

New insights into the role of non-coding RNAs as transcriptional targets of p53

Contact Info

Product

Resources

About